MYWOT
Child safety
Confidence
Trustworthiness
Confidence
MALICIOUS CONTENT INDICATORS
Ctibiopharma.com most likely does not offer any malicious content.
Secure connection support
HTTPS
Ctibiopharma.com provides SSL-encrypted connection.
ADULT CONTENT INDICATORS
Ctibiopharma.com most likely does not offer any adult content.
Audience
-
Time on site
01:10
AVG
-
Gender
Men
N/A
Women
N/A
Popular pages
-
CTI BioPharma | Targeted Blood Cancer Therapies | Home
CTI BioPharma focuses on the acquisition, development and commercialization of therapies for blood-related cancers that offer unique benefits to patients.
-
CTI BioPharma | Novel Therapies for Myelofibrosis | About
About us We are on a mission to make a meaningful impact on the lives of patients with blood-related cancers. At CTI, we are resolute in our commitment to deliver new medicines to patients with blood...
-
CTI BioPharma | Targeted Blood Cancer Therapy | Development
OVERVIEW Patients and families living with blood-related cancers inspire us to acquire, develop and commercialize novel therapeutics. Our pursuit of advancing novel treatments for blood-cancers begins...
-
CTI BioPharma | Novel Blood Cancer Therapy | Clinical Trials
PACIFICA Trial for myelofibrosis conducted by CTI BioPharma, a developer of therapies for blood-related cancers that offer unique benefits to patients.
-
CTI BioPharma | Targeted Blood Cancer Therapy | Our Culture
OUR CULTURE At CTI we are united by our commitment to patients and are inspired to make a meaningful impact, together. We start with patients. Our dedicated team shows up every day motivated to make a...
-
CTI BioPhama | Novel Targeted Therapies for Myelofibrosis
MYELOFIBROSIS PROGRAM Our novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1, is approved for the treatment of myelofibrosis patients with cytopenic myelofibrosis...